The response of human decidual leukocytes to IL-2.

[1]  A. Nagler,et al.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. , 1991, Journal of Clinical Investigation.

[2]  S. Burdach,et al.  Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor. , 1991, The Journal of clinical investigation.

[3]  D. Longo,et al.  Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. , 1991, Journal of immunology.

[4]  P. Starkey Expression on cells of early human pregnancy decidua, of the p75, IL-2 and p145, IL-4 receptor proteins. , 1991, Immunology.

[5]  T. Waldmann,et al.  The interleukin-2 receptor. , 1991, The Journal of biological chemistry.

[6]  T. Chisesi,et al.  Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. , 1990, Blood.

[7]  A. Uchida,et al.  Studies on T‐Lineage Cells in Human Decidua of First Trimester Pregnancies , 1990, American journal of reproductive immunology.

[8]  S. Strom,et al.  Interleukin-1β, human leukocyte antigen HLA-DRα, and transforming growth factor-β expression in endom trium, placenta, and placental membranes , 1990 .

[9]  A. Meager,et al.  Phenotypic and functional analysis of human CD3- decidual leucocyte clones. , 1990, Immunology.

[10]  K. Sugamura,et al.  Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL- 2 binding , 1990, The Journal of experimental medicine.

[11]  Y. W. Loke,et al.  Human trophoblast and JEG choriocarcinoma cells are sensitive to lysis by IL-2-stimulated decidual NK cells. , 1990, Cellular immunology.

[12]  B. Ferry,et al.  Cell populations in the human early pregnancy decidua: natural killer activity and response to interleukin-2 of CD56-positive large granular lymphocytes. , 1990, Immunology.

[13]  K. Sugamura,et al.  Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets. , 1990, International immunology.

[14]  H. Umehara,et al.  The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. , 1990, Immunology.

[15]  J. Sosman,et al.  Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. , 1990, Cancer research.

[16]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[17]  L. Lanier,et al.  Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo , 1990, The Journal of experimental medicine.

[18]  S. Tabibzadeh Proliferative activity of lymphoid cells in human endometrium throughout the menstrual cycle. , 1990, The Journal of clinical endocrinology and metabolism.

[19]  L. Lanier,et al.  Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.

[20]  J. Sosman,et al.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. , 1989, Cancer research.

[21]  K. Sugamura,et al.  Activation of natural killer cells via the p75 interleukin 2 receptor , 1989, The Journal of experimental medicine.

[22]  R. Fisher,et al.  Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. , 1989, Journal of immunology.

[23]  H. Asao,et al.  Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor , 1989, The Journal of experimental medicine.

[24]  L. Gardner,et al.  Immunocytochemical characterization of the unusual large granular lymphocytes in human endometrium throughout the menstrual cycle. , 1989, Human immunology.

[25]  G. Janossy,et al.  Cellular events during memory T-cell activation in vitro: the UCHL1 (180,000 MW) determinant is newly synthesized after mitosis. , 1989, Immunology.

[26]  Y. W. Loke,et al.  Early human decidual cells exhibit NK activity against the K562 cell line but not against first trimester trophoblast. , 1989, Cellular immunology.

[27]  C. Morimoto,et al.  Characterization of CD45 and CD45R monoclonal antibodies using transfected mouse cell lines that express individual human leukocyte common antigens. , 1988, Journal of immunology.

[28]  R. Fisher,et al.  Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. , 1988, Cancer research.

[29]  J. Bulmer,et al.  Endometrial granulocytes in human decidua react with a natural-killer (NK) cell marker, NKH1. , 1987, Immunology.

[30]  J. Bulmer,et al.  The T-lymphocyte population in first-trimester human decidua does not express the interleukin-2 receptor. , 1986, Immunology.

[31]  N. Carter,et al.  CD3- Leukocytes Present in the Human Uterus During Early Placentation: Phenotypic and Morphologic Characterization of the CD56++ Population , 1991, Developmental immunology.